Life Science Compliance Update

« Previous article | Home| Next article »

April 28, 2016

Tick-tock - The Role of Compliance in M&A


In this article, we review advice from industry thought leaders on (1) how to ensure compliance officers are a part of the process and not just brought in at the eleventh hour; (2) what to do if the compliance officer is brought in at the last minute; (3) what data a compliance officer should be collecting pre-close; and (4) what data will likely not be made available pre-close, but should remain top priorities.

For compliance officers ("CO"), access to information is essential, but in a fast-moving acquisition deal gaining access to needed data is not always easy. Compliance concerns are not always prioritized before a deal is made though CO's are often called on after the deal to ensure a smooth transition. But it's even more important for compliance to have a seat at the pre-deal table. As William Intner, a partner at Hogan Lovells, told listeners at the Pharmaceutical Compliance Congress and Best Practices Forum in October, "There's only so much protection you get from the warranties of a contract. Dollars behind a representation won't fix the lost sales or the CIA or whatever the parade of carnivals that can come with the later-discovered compliance problems."

To Read the Full Story, Subscribe, Download a Sample Issue, or Sign In

« Previous article | Home| Next article »


Feed You can follow this conversation by subscribing to the comment feed for this post.

The comments to this entry are closed.


Preview | Powered by FeedBlitz


April 2018
Sun Mon Tue Wed Thu Fri Sat
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30